{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:39:38Z","timestamp":1792798778704,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"DOI":"10.1186\/s12906-026-05294-6","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T08:35:29Z","timestamp":1770798929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Buddlejasaponin IV inhibits proliferation and migration via STAT3 suppression in gefitinib-resistant non-small cell lung cancer cells"],"prefix":"10.1186","volume":"26","author":[{"given":"Sung Chul","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghwa","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeho","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyun","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Seo","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae Won","family":"Ock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyen Joo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"13","key":"5294_CR1","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1056\/NEJMra0802714","volume":"359","author":"RS Herbst","year":"2008","unstructured":"Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367\u201380.","journal-title":"N Engl J Med"},{"issue":"2","key":"5294_CR2","first-page":"110","volume":"4","author":"CN Prabhakar","year":"2015","unstructured":"Prabhakar CN. Epidermal growth factor receptor in non-small cell lung cancer. Transl Lung Cancer Res. 2015;4(2):110\u20138.","journal-title":"Transl Lung Cancer Res"},{"key":"5294_CR3","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","volume":"290","author":"MG Kris","year":"2003","unstructured":"Kris MG, Natale RB, Herbst RS, Lynch JT Jr., Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, et al. Efficacy of Gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine Kinase, in symptomatic patients with Non\u2013Small cell lung cancer: A randomized trial. JAMA. 2003;290:2149\u201358.","journal-title":"JAMA"},{"issue":"2","key":"5294_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santab\u00e1rbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123\u201332.","journal-title":"N Engl J Med"},{"issue":"2","key":"5294_CR5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.lungcan.2009.05.022","volume":"68","author":"T Onitsuka","year":"2010","unstructured":"Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K, Yasumoto K. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer. 2010;68(2):198\u2013203.","journal-title":"Lung Cancer"},{"issue":"9","key":"5294_CR6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1172\/JCI0215650","volume":"109","author":"DE Levy","year":"2002","unstructured":"Levy DE, Lee CK. What does Stat3 do? J Clin Invest. 2002;109(9):1143\u20138.","journal-title":"J Clin Invest"},{"issue":"2","key":"5294_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3390\/ijms22020603","volume":"22","author":"M Tolomeo","year":"2021","unstructured":"Tolomeo M, Cascio A. The multifaced role of STAT3 in cancer and its implication for anticancer therapy. Int J Mol Sci. 2021;22(2):603.","journal-title":"Int J Mol Sci"},{"key":"5294_CR8","doi-asserted-by":"crossref","unstructured":"Wang HQ, Man QW, Huo FY, Gao X, Lin H, Li SR, Wang J, Su FC, Cai L, Shi Y, Liu B, Bu LL. STAT3 pathway in cancers: Past, present, and future. MedComm (2020). 2022;3(2):e124.","DOI":"10.1002\/mco2.124"},{"key":"5294_CR9","doi-asserted-by":"publisher","first-page":"421821","DOI":"10.1155\/2013\/421821","volume":"2013","author":"MZ Kamran","year":"2013","unstructured":"Kamran MZ, Patil P, Gude RP. Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int. 2013;2013:421821.","journal-title":"Biomed Res Int"},{"issue":"23","key":"5294_CR10","doi-asserted-by":"publisher","first-page":"8288","DOI":"10.1158\/1078-0432.CCR-05-0827","volume":"11","author":"EB Haura","year":"2005","unstructured":"Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res. 2005;11(23):8288\u201394.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5294_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","volume":"26","author":"HJ Lee","year":"2014","unstructured":"Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014;26(2):207\u201321.","journal-title":"Cancer Cell"},{"issue":"2","key":"5294_CR12","doi-asserted-by":"publisher","first-page":"824","DOI":"10.7150\/thno.49600","volume":"11","author":"Q Zheng","year":"2021","unstructured":"Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, Shi S, Zhu K, Qu X, Hu W, Liu P, Wang Y, Zhang X. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics. 2021;11(2):824\u201340.","journal-title":"Theranostics"},{"issue":"20","key":"5294_CR13","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1038\/s41388-020-1271-y","volume":"39","author":"C Zhao","year":"2020","unstructured":"Zhao C, Yang L, Zhou F, Yu Y, Du X, Xiang Y, Li C, Huang X, Xie C, Liu Z, Lin J, Wang L, Liang G, Cui R. Feedback activation of EGFR is the main cause for STAT3 inhibition-irresponsiveness in pancreatic cancer cells. Oncogene. 2020;39(20):3997\u20134013.","journal-title":"Oncogene"},{"key":"5294_CR14","doi-asserted-by":"publisher","first-page":"216612","DOI":"10.1016\/j.canlet.2024.216612","volume":"586","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhou Q, Liu C, Zhang R, Xing B, Du J, Dong L, Zheng J, Chen Z, Sun M, Yao X, Ren Y, Zhou X. Targeting IL-6\/STAT3 signaling abrogates EGFR-TKI resistance through inhibiting Beclin-1 dependent autophagy in HNSCC. Cancer Lett. 2024;586:216612.","journal-title":"Cancer Lett"},{"issue":"12","key":"5294_CR15","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s12272-017-0943-9","volume":"41","author":"YD Zhu","year":"2018","unstructured":"Zhu YD, Hong JY, Bao FD, Xing N, Wang LT, Sun ZH, Luo Y, Jiang H, Xu XD, Zhu NL, Wu HF, Sun GB, Yang JS. Triterpenoid saponins from clinopodium Chinense (Benth.) O. Kuntze and their biological activity. Arch Pharm Res. 2018;41(12):1117\u201330.","journal-title":"Arch Pharm Res"},{"key":"5294_CR16","doi-asserted-by":"publisher","first-page":"116330","DOI":"10.1016\/j.jep.2023.116330","volume":"309","author":"Y Wang","year":"2023","unstructured":"Wang Y, Shao Z, Song C, Zhou H, Zhao J, Zong K, Zhou G, Meng D. Clinopodium Chinense Kuntze ameliorates dextran sulfate sodium-induced ulcerative colitis in mice by reducing systematic inflammation and regulating metabolism. J Ethnopharmacol. 2023;309:116330.","journal-title":"J Ethnopharmacol"},{"key":"5294_CR17","doi-asserted-by":"publisher","first-page":"116489","DOI":"10.1016\/j.jep.2023.116489","volume":"312","author":"L Li","year":"2023","unstructured":"Li L, Qi J, Tao H, Wang L, Wang L, Wang N, Huang Q. Protective effect of the total flavonoids from clinopodium Chinense against LPS-induced mice endometritis by inhibiting NLRP3 inflammasome-mediated pyroptosis. J Ethnopharmacol. 2023;312:116489.","journal-title":"J Ethnopharmacol"},{"key":"5294_CR18","doi-asserted-by":"publisher","first-page":"105736","DOI":"10.1016\/j.fitote.2023.105736","volume":"172","author":"M Shen","year":"2024","unstructured":"Shen M, Zheng C, Hao Z, Song H, Wang Y, Meng D. Undescribed compounds from clinopodium Chinense (Benth.) O. Kuntze and their coagulation activity studies. Fitoterapia. 2024;172:105736.","journal-title":"Fitoterapia"},{"issue":"7","key":"5294_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/14786419.2013.879132","volume":"28","author":"M Zhong","year":"2014","unstructured":"Zhong M, Wu H, Zhang X, Sun G, Sun G, Yu S, Xu X. A new diterpene from clinopodium Chinense. Nat Prod Res. 2014;28(7):467\u201372.","journal-title":"Nat Prod Res"},{"issue":"9","key":"5294_CR20","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/14786419.2015.1095745","volume":"30","author":"B Zeng","year":"2016","unstructured":"Zeng B, Liu GD, Zhang BB, Wang SS, Ma R, Zhong BS, He BQ, Liang Y, Wu FH. A new triterpenoid saponin from clinopodium Chinense (Benth.) O. Kuntze. Nat Prod Res. 2016;30(9):1001\u20138.","journal-title":"Nat Prod Res"},{"issue":"1","key":"5294_CR21","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.3390\/molecules20011610","volume":"20","author":"M Chudzik","year":"2015","unstructured":"Chudzik M, Korzonek-Szlacheta I, Kr\u00f3l W. Triterpenes as potentially cytotoxic compounds. Molecules. 2015;20(1):1610\u201325.","journal-title":"Molecules"},{"issue":"2","key":"5294_CR22","first-page":"93","volume":"51","author":"D Kim","year":"2020","unstructured":"Kim D, Lee SK, Park K-S, Park H-J. Isolation of the constituents from clinopodium Chinense var. Shibetchense and Inhibition activity on cancer cell growth and nitric oxide production. Kor J Pharmacogn. 2020;51(2):93\u20139.","journal-title":"Kor J Pharmacogn"},{"issue":"2","key":"5294_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/sj.bjp.0706718","volume":"148","author":"JH Won","year":"2006","unstructured":"Won JH, Im HT, Kim YH, Yun KJ, Park HJ, Choi JW, Lee KT. Anti-inflammatory effect of Buddlejasaponin IV through the Inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via the NF-kappaB inactivation. Br J Pharmacol. 2006;148(2):216\u201325.","journal-title":"Br J Pharmacol"},{"issue":"10","key":"5294_CR24","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/ptr.3406","volume":"25","author":"YS Hwang","year":"2011","unstructured":"Hwang YS, Chung WY, Kim J, Park HJ, Kim EC, Park KK. Buddlejasaponin IV induces cell cycle arrest at G2\/M phase and apoptosis in immortalized human oral keratinocytes. Phytother Res. 2011;25(10):1503\u201310.","journal-title":"Phytother Res"},{"issue":"3","key":"5294_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3892\/or.2023.8495","volume":"49","author":"JE Kim","year":"2023","unstructured":"Kim JE, Lee SK, Park J, Jung MJ, An SE, Yang HJ, Chung WY. Buddlejasaponin IV induces apoptotic cell death by activating the mitochondrial-dependent apoptotic pathway and reducing \u03b12\u03b21 integrin-mediated adhesion in HT-29 human colorectal cancer cells. Oncol Rep. 2023;49(3):58.","journal-title":"Oncol Rep"},{"issue":"5","key":"5294_CR26","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1021\/acs.jnatprod.2c00224","volume":"85","author":"WS Byun","year":"2022","unstructured":"Byun WS. Antitumor activity of Rutaecarpine in human colorectal cancer cells by suppression of Wnt\/\u03b2-Catenin signaling. J Nat Prod. 2022;85(5):1407\u201318.","journal-title":"J Nat Prod"},{"key":"5294_CR27","doi-asserted-by":"publisher","first-page":"114039","DOI":"10.1016\/j.biopha.2022.114039","volume":"157","author":"ES Bae","year":"2023","unstructured":"Bae ES. Periplocin exerts antitumor activity by regulating Nrf2-mediated signaling pathway in gemcitabine-resistant pancreatic cancer cells. Biomed Pharmacother. 2023;157:114039.","journal-title":"Biomed Pharmacother"},{"key":"5294_CR28","doi-asserted-by":"publisher","first-page":"106573","DOI":"10.1016\/j.bioorg.2023.106573","volume":"137","author":"J Song","year":"2023","unstructured":"Song J. Synthesis and biological evaluation of atropisomeric tetrahydroisoquinolines overcoming docetaxel resistance in triple-negative human breast cancer cells. Bioorg Chem. 2023;137:106573.","journal-title":"Bioorg Chem"},{"issue":"4","key":"5294_CR29","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1021\/acs.jmedchem.2c01115","volume":"66","author":"WS Byun","year":"2023","unstructured":"Byun WS, Design. Synthesis, and biological activity of Marinacarboline analogues as STAT3 pathway inhibitors for Docetaxel-Resistant Triple-Negative breast cancer. J Med Chem. 2023;66(4):3106\u201333.","journal-title":"J Med Chem"},{"key":"5294_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621\u201381.","journal-title":"Pharmacol Rev"},{"issue":"34","key":"5294_CR31","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1038\/sj.onc.1209608","volume":"25","author":"S Fulda","year":"2006","unstructured":"Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25(34):4798\u2013811.","journal-title":"Oncogene"},{"issue":"6","key":"5294_CR32","doi-asserted-by":"publisher","first-page":"100773","DOI":"10.1016\/j.tranon.2020.100773","volume":"13","author":"D Ribatti","year":"2020","unstructured":"Ribatti D, Tamma R, Annese T. Epithelial-Mesenchymal transition in cancer: A historical overview. Transl Oncol. 2020;13(6):100773.","journal-title":"Transl Oncol"},{"issue":"13","key":"5294_CR33","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/sj.onc.1205260","volume":"21","author":"G Niu","year":"2002","unstructured":"Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21(13):2000\u20138.","journal-title":"Oncogene"},{"issue":"1","key":"5294_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10198-019-01117-3","volume":"21","author":"MS Holleman","year":"2020","unstructured":"Holleman MS, Al MJ, Zaim R, Groen HJM, Uyl-de Groot CA. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. Eur J Health Econ. 2020;21(1):153\u201364.","journal-title":"Eur J Health Econ"},{"key":"5294_CR35","doi-asserted-by":"publisher","first-page":"819674","DOI":"10.3389\/fonc.2022.819674","volume":"12","author":"H Guan","year":"2022","unstructured":"Guan H, Wang C, Chen C, Han S, Zhao Z. Cost-Effectiveness of 12 First-Line treatments for patients with advanced EGFR mutated NSCLC in the united Kingdom and China. Front Oncol. 2022;12:819674.","journal-title":"Front Oncol"},{"issue":"2","key":"5294_CR36","first-page":"136","volume":"1845","author":"KS Siveen","year":"2014","unstructured":"Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G, Bishayee A. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta. 2014;1845(2):136\u201354.","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"5294_CR37","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nbt.2284","volume":"30","author":"B Al-Lazikani","year":"2012","unstructured":"Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30(7):679\u201392.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"5294_CR38","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.3390\/ijms24054722","volume":"24","author":"S Singh","year":"2023","unstructured":"Singh S, Gomez HJ, Thakkar S, Singh SP, Parihar AS. Overcoming acquired drug resistance to cancer therapies through targeted STAT3 Inhibition. Int J Mol Sci. 2023;24(5):4722.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5294_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihim\u00e4ki","year":"2014","unstructured":"Riihim\u00e4ki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78\u201384.","journal-title":"Lung Cancer"},{"key":"5294_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.critrevonc.2018.09.017","volume":"132","author":"S Norouzi","year":"2018","unstructured":"Norouzi S, Gorgi Valokala M, Mosaffa F, Zirak MR, Zamani P, Behravan J. Crosstalk in cancer resistance and metastasis. Crit Rev Oncol Hematol. 2018;132:145\u201353.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"5294_CR41","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000515289","volume":"211","author":"MK Jolly","year":"2022","unstructured":"Jolly MK, Murphy RJ, Bhatia S, Whitfield HJ, Redfern A, Davis MJ, Thompson EW. Measuring and modelling the Epithelial- mesenchymal hybrid state in cancer: clinical implications. Cells Tissues Organs. 2022;211(2):110\u201333.","journal-title":"Cells Tissues Organs"},{"issue":"2","key":"5294_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"5294_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15(1):129.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"5294_CR44","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611\u201329.","journal-title":"Nat Rev Clin Oncol"},{"issue":"24","key":"5294_CR45","doi-asserted-by":"publisher","first-page":"6228","DOI":"10.3390\/cancers13246228","volume":"13","author":"S Parakh","year":"2021","unstructured":"Parakh S, Ernst M, Poh AR. Multicellular effects of STAT3 in Non-small cell lung cancer: mechanistic insights and therapeutic opportunities. Cancers (Basel). 2021;13(24):6228.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"5294_CR46","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3892\/ol.2021.12932","volume":"22","author":"JE Cha","year":"2021","unstructured":"Cha JE, Bae WY, Choi JS, Lee SH, Jeong JW. Angiogenic activities are increased via upregulation of HIF-1\u03b1 expression in gefitinib-resistant non-small cell lung carcinoma cells. Oncol Lett. 2021;22(3):671.","journal-title":"Oncol Lett"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-026-05294-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-026-05294-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-026-05294-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:02:48Z","timestamp":1773799368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12906-026-05294-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5294"],"URL":"https:\/\/doi.org\/10.1186\/s12906-026-05294-6","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}